Vasomotor Symptoms Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety And Efficacy Of DVS SR For The Treatment Of Vasomotor Symptoms Associated With Menopause
Verified date | July 2011 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
Status | Completed |
Enrollment | 2186 |
Est. completion date | May 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 45 Years and older |
Eligibility |
Inclusion Criteria: - Generally healthy, postmenopausal women who seek treatment for hot flushes - Body Mass Index (BMI) less than or equal to 34 kg/m^2 Exclusion Criteria: - Hypersensitivity to Venlafaxine - Myocardial infarction an/or unstable angina within 6 months of screening - History of seizure disorder |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Pfizer Investigational Site | Antigonish | Nova Scotia |
Canada | Pfizer Investigational Site | Calgary | Alberta |
Canada | Pfizer Investigational Site | Coquitlam | British Columbia |
Canada | Pfizer Investigational Site | Corunna | Ontario |
Canada | Pfizer Investigational Site | Gatineau | Quebec |
Canada | Pfizer Investigational Site | L'Ancienne-Lorette | Quebec |
Canada | Pfizer Investigational Site | Ottawa | Ontario |
Canada | Pfizer Investigational Site | Pointe Claire | Quebec |
Canada | Pfizer Investigational Site | Quebec | |
Canada | Pfizer Investigational Site | Saint-Janvier | Quebec |
Canada | Pfizer Investigational Site | Sarnia | Ontario |
Canada | Pfizer Investigational Site | Shawinigan | Quebec |
Canada | Pfizer Investigational Site | Sherbrooke | Quebec |
Canada | Pfizer Investigational Site | St-Romuald | Quebec |
Canada | Pfizer Investigational Site | Surrey | British Columbia |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Winnipeg | Manitoba |
United States | Pfizer Investigational Site | Akron | Ohio |
United States | Pfizer Investigational Site | Albuquerque | New Mexico |
United States | Pfizer Investigational Site | Ann Arbor | Michigan |
United States | Pfizer Investigational Site | Atlanta | Georgia |
United States | Pfizer Investigational Site | Billings | Montana |
United States | Pfizer Investigational Site | Billings | Montana |
United States | Pfizer Investigational Site | Birmingham | Alabama |
United States | Pfizer Investigational Site | Bismarck | North Dakota |
United States | Pfizer Investigational Site | Boise | Idaho |
United States | Pfizer Investigational Site | Brooklyn Center | Minnesota |
United States | Pfizer Investigational Site | Brooksville | Florida |
United States | Pfizer Investigational Site | Burlington | Vermont |
United States | Pfizer Investigational Site | Chattanooga | Tennessee |
United States | Pfizer Investigational Site | Cincinnati | Ohio |
United States | Pfizer Investigational Site | Clearwater | Florida |
United States | Pfizer Investigational Site | Clearwater | Florida |
United States | Pfizer Investigational Site | Cleveland | Ohio |
United States | Pfizer Investigational Site | Colorado Springs | Colorado |
United States | Pfizer Investigational Site | Creve Coeur | Missouri |
United States | Pfizer Investigational Site | Dallas | Texas |
United States | Pfizer Investigational Site | Daytona Beach | Florida |
United States | Pfizer Investigational Site | Decatur | Georgia |
United States | Pfizer Investigational Site | Decatur | Georgia |
United States | Pfizer Investigational Site | Denver | Colorado |
United States | Pfizer Investigational Site | Englewood | Colorado |
United States | Pfizer Investigational Site | Englewood | Ohio |
United States | Pfizer Investigational Site | Erie | Pennsylvania |
United States | Pfizer Investigational Site | Erie | Pennsylvania |
United States | Pfizer Investigational Site | Eugene | Oregon |
United States | Pfizer Investigational Site | Fargo | North Dakota |
United States | Pfizer Investigational Site | Fort Myers | Florida |
United States | Pfizer Investigational Site | Gainesville | Florida |
United States | Pfizer Investigational Site | Glendale | Arizona |
United States | Pfizer Investigational Site | Greer | South Carolina |
United States | Pfizer Investigational Site | Hilton Head Island | South Carolina |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Idaho Falls | Idaho |
United States | Pfizer Investigational Site | Indianapolis | Indiana |
United States | Pfizer Investigational Site | Indianapolis | Indiana |
United States | Pfizer Investigational Site | Jamestown | North Dakota |
United States | Pfizer Investigational Site | Jenkintown | Pennsylvania |
United States | Pfizer Investigational Site | Jonesboro | Arkansas |
United States | Pfizer Investigational Site | Knoxville | Tennessee |
United States | Pfizer Investigational Site | Lake Worth | Florida |
United States | Pfizer Investigational Site | Las Vegas | Nevada |
United States | Pfizer Investigational Site | Las Vegas | Nevada |
United States | Pfizer Investigational Site | Lebanon | New Hampshire |
United States | Pfizer Investigational Site | Lexington | Kentucky |
United States | Pfizer Investigational Site | Lincoln | Nebraska |
United States | Pfizer Investigational Site | Little Rock | Arkansas |
United States | Pfizer Investigational Site | Little Rock | Arkansas |
United States | Pfizer Investigational Site | Longmont | Colorado |
United States | Pfizer Investigational Site | Louisville | Kentucky |
United States | Pfizer Investigational Site | Medford | Oregon |
United States | Pfizer Investigational Site | Menomonee Falls | Wisconsin |
United States | Pfizer Investigational Site | Midland | Texas |
United States | Pfizer Investigational Site | Mobile | Alabama |
United States | Pfizer Investigational Site | Montgomery | Alabama |
United States | Pfizer Investigational Site | Nashville | Tennessee |
United States | Pfizer Investigational Site | New Brunswick | New Jersey |
United States | Pfizer Investigational Site | New London | Connecticut |
United States | Pfizer Investigational Site | New Orleans | Louisiana |
United States | Pfizer Investigational Site | New Port Richey | Florida |
United States | Pfizer Investigational Site | New York | New York |
United States | Pfizer Investigational Site | Newark | Delaware |
United States | Pfizer Investigational Site | Norfolk | Virginia |
United States | Pfizer Investigational Site | Norfolk | Virginia |
United States | Pfizer Investigational Site | Oklahoma City | Oklahoma |
United States | Pfizer Investigational Site | Overland Park | Kansas |
United States | Pfizer Investigational Site | Palm Harbor | Florida |
United States | Pfizer Investigational Site | Pembroke Pines | Florida |
United States | Pfizer Investigational Site | Peoria | Arizona |
United States | Pfizer Investigational Site | Philadelphia | Pennsylvania |
United States | Pfizer Investigational Site | Pittsburgh | Pennsylvania |
United States | Pfizer Investigational Site | Plano | Texas |
United States | Pfizer Investigational Site | Reno | Nevada |
United States | Pfizer Investigational Site | Richmond | Virginia |
United States | Pfizer Investigational Site | Salt Lake City | Utah |
United States | Pfizer Investigational Site | San Antonio | Texas |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | Sandy | Utah |
United States | Pfizer Investigational Site | Savannah | Georgia |
United States | Pfizer Investigational Site | Scarborough | Maine |
United States | Pfizer Investigational Site | Seattle | Washington |
United States | Pfizer Investigational Site | Sioux Falls | South Dakota |
United States | Pfizer Investigational Site | Sioux Falls | South Dakota |
United States | Pfizer Investigational Site | South Bend | Indiana |
United States | Pfizer Investigational Site | South Miami | Florida |
United States | Pfizer Investigational Site | Tampa | Florida |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Vista | California |
United States | Pfizer Investigational Site | Waco | Texas |
United States | Pfizer Investigational Site | Walnut Creek | California |
United States | Pfizer Investigational Site | Warwick | Rhode Island |
United States | Pfizer Investigational Site | Watertown | South Dakota |
United States | Pfizer Investigational Site | West Palm Beach | Florida |
United States | Pfizer Investigational Site | Wexford | Pennsylvania |
United States | Pfizer Investigational Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4 | The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. | Baseline and Week 4 | No |
Primary | Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12 | The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. | Baseline and Week 12 | No |
Primary | Change From Baseline in the Average Daily Severity of Hot Flushes at Week 4 | Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes. | Baseline and Week 4 | No |
Primary | Change From Baseline in the Average Daily Severity of Hot Flushes at Week 12 | Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes. | Baseline and Week 12 | No |
Primary | Number of Participants With All Adjudicated Ischemic Cardiovascular (CV) Events | Adjudicated ischemic cardiovascular events were a composite of: a) Coronary Heart Disease (CHD)-related death; b) New Myocardial Infarction (MI) (non-procedure-related MI); c) Documented new onset of unstable angina requiring hospitalization; d) Unscheduled coronary revascularization procedures (percutaneous coronary intervention) or bypass grafting. | Baseline up to Month 12 | Yes |
Secondary | Number of Participants With a Minimal Clinically Meaningful Decrease in the Average Daily Number of Hot Flushes | A mean decrease from baseline of at least 5.35 moderate to severe hot flushes at week 12 in the participants was considered clinically meaningful. | Baseline and Week 12 | No |
Secondary | Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes | The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. | Baseline, Week 4 and Week 12 | No |
Secondary | Percentage of Participants With at Least 75% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes | The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. | Baseline, Week 4 and Week 12 | No |
Secondary | Median Time to the First Day of 3 Consecutive Days of at Least 50% Reduction in Hot Flushes | Time to response was defined as the time-to-first 50% reduction in the average daily number of moderate to severe hot flushes over 3 consecutive days. | Week 12 | No |
Secondary | Change From Baseline in Adjusted Means in the Number of Moderate and Severe Hot Flushes at Month 6 and Month 12 | The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. Adjusted mean was calculated by using change from baseline as response variable, treatment as factor, and baseline as covariate using the observed cases. | Baseline, Month 6 and Month 12 | No |
Secondary | Change From Baseline in Adjusted Means in the Hot Flush Severity Score at Month 6 and Month 12 | Severity: mild (heat sensation without sweating); moderate (heat sensation with sweating; able to continue activity); severe (heat sensation with sweating; causing cessation of activity). Average daily severity of hot flushes= (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). Days with no hot flushes: severity score=0. As it was derived from count data, there was no maximum; minimum score=0; higher values= worse outcomes. Adjusted mean: calculated using change from baseline=response variable, treatment=factor and baseline=covariate using observed cases. | Baseline, Month 6 and Month 12 | No |
Secondary | Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Week 12 | GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms. | Baseline and Week 12 | No |
Secondary | Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 6 | GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms. | Baseline and Month 6 | No |
Secondary | Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 12 | GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms. | Baseline and Month 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Week 12 | PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe). | Week 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 6 | PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe). | Month 6 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 12 | PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe). | Month 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Week 12 | PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe). | Week 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 6 | PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe). | Month 6 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 12 | PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe). | Month 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Week 12 | PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse). | Week 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 6 | PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse). | Month 6 | No |
Secondary | Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 12 | PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse). | Month 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Week 12 | PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse). | Week 12 | No |
Secondary | Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 6 | PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse). | Month 6 | No |
Secondary | Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 12 | PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse). | Month 12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04090957 -
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01052454 -
Mindfulness-Based Stress Reduction for Hot Flashes
|
Phase 0 | |
Completed |
NCT00535288 -
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
|
Phase 3 | |
Recruiting |
NCT00906308 -
A Study of MF101 in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01452373 -
Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00560833 -
Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
|
Phase 3 | |
Completed |
NCT05033886 -
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
|
Phase 3 | |
Completed |
NCT05083884 -
A Survey About Hot Flashes in Women Going Through the Menopause
|
||
Completed |
NCT01178892 -
MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation
|
N/A | |
Completed |
NCT00397176 -
Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women
|
Phase 1 | |
Recruiting |
NCT06122181 -
Study of HS-10384 in Participants of Chinese Postmenopausal Women
|
Phase 1 | |
Not yet recruiting |
NCT06393673 -
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women
|
Phase 2 | |
Withdrawn |
NCT02202707 -
Vasomotor Symptoms and Cardiovascular Control
|
N/A | |
Completed |
NCT00356447 -
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
|
Phase 3 | |
Completed |
NCT05312567 -
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
|
Phase 2 | |
Terminated |
NCT01353963 -
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
|
Phase 4 | |
Completed |
NCT00446199 -
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
|
Phase 3 | |
Completed |
NCT05850338 -
Determination of the Effects of Autogenic Relaxation Exercise and Cold Pillow Application on Vasomotor Symptom Control and Quality of Life in Postmenopausal Women
|
N/A | |
Completed |
NCT02803268 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
|
Phase 1 | |
Completed |
NCT03512002 -
HIRREM Hot Flashes Study
|
N/A |